Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2020 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in Two September Virtual Investor Conferences

NEW YORK and LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
September 01, 2020 08:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress

International clinical development program of nomacopan for the potential treatment of COVID-19 pneumonia announcedPivotal Phase III study in patients with bullous pemphigoid (BP) expected to start H1...
August 31, 2020 07:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia

Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and Brazil Proposed multi-center U.S. randomized clinical program in regulatory submission following...
August 12, 2020 08:23 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan

Phase III randomized placebo-controlled study in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of complete disease remission on minimal oral corticosteroids (OCS) agreed...
July 01, 2020 09:16 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and...
July 01, 2020 09:15 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Appointment of Chief Financial Officer

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and...
May 29, 2020 07:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress

Open pivotal study in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval Preparing for pivotal study in bullous pemphigoid...
May 21, 2020 11:32 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid

NEW YORK and LONDON, May 21, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
May 04, 2020 07:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series

NEW YORK and LONDON, May 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
May 01, 2020 07:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction in...